Glioblastoma: Report on current research program

brain Glioblastoma cancer pao pereira

Several fundamental studies over 20 years by Mirko Beljanski PhD aimed to study what the plant extract Pao pereira could bring to the treatment of brain tumors, especially glioblastoma (GMB). This is the most common and aggressive type of cancer, affecting neuron-support cells called astrocytes. The 1-year and 2-year relative survival rates for GBM are 29.6% and 9.0%, respectively. Only 3.4% of patients with a GBM diagnosis survive more than 5 years.(1,2)

The Beljanski Foundation is collaborating with researchers at the University of California at San Francisco to study the effectiveness of a plant extract, Pao pereira against glioblastoma. This extract was originally developed by French scientist Mirko Beljanski at the Pasteur Institute in Paris. He showed that the Pao pereira extract has a broad spectrum of anti-cancer activity.(3)

Preclinical cell-based studies at UCSF are positive and it has been decided to move forward with an animal model. Exciting results are expected by fall.

For any agent to be successful against brain cancer it must cross the blood-brain barrier—a natural filter that prevents potentially harmful molecules from entering the brain. Beljanski showed that the active compounds in his Pao pereira extract do cross the blood brain barrier and so may exert their anti-tumor effect on brain cancers, including glioblastoma. This observation is critical to the success of the animal studies at UCSF.

Our work is made possible by the generous donations of individuals who believe in the mission of The Beljanski Foundation and share our commitment to making the discoveries of Professor Beljanski available to as many people as possible.

The Beljanski Foundation, Inc. is a 501(c)(3) non-profit organization. Contributions are tax deductible to the fullest extent allowed by law. For more information on The Beljanski Foundation, or to interview Sylvie Beljanski, please contact us.


REFERENCES
(1) Central Brain Tumor Registry of the United States. 2007-2008 Primary Brain Tumors in the United States: Statistical report. [online] 2008. Available at: http://www.cbtrus.org/reports//2007-2008/2007report.pdf. Accessed October 23, 2008.
(2) Louis DN, Ohaki H, Wiestler OD, et al. The 2007 WHO Classification of Tumours of the central nervous system. Acta Neuropathologica 2007;114:97-109.
(3) “Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer” by Jun Yu, PhD and Qi Chen, PhD – Integrative Cancer Therapy. 2014 Apr 24;13(3):217-225.
“Inhibition of Pancreatic Cancer and Potentiation of Gemcitabine Effects by the Extract of Pao Pereira” by JUN YU, JEANNE DRISKO and QI CHEN – Oncology Reports” Journal (doi: 10.3892/or.2013.2461)
“B-Carboline Alkaloid-Enriched Extract from the Amazonian Rain Forest Tree Pao Pereira Suppresses Prostate Cancer Cells” by Debra L. Bemis, PhD, Jillian L. Capodice, LAc, MS, Manisha Desai, PhD, Aaron E. Katz, MD, Ralph Buttyan, PhD – Journal of the Society for Integrative Oncology, Vol 7, No2
“Antitumor Activities of Rauwolfia Vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer” by Yu J, Ma Y, Drisko J, Chen Q. – Curr Ther Res Clin Exp. 2013 Dec;75:8-14. doi: 10.1016/j.curtheres.2013.04.001.
“The Plant Extract of Pao Pereira Potentiates Carboplatin Effects Against Ovarian Cancer” published by Informa Healthcare USA, Inc. by Jun Yu, PhD, Qi Chen, PhD.  – ISSN 1388-0209 print/ISSN 1744-5116 –
Pharmaceutical Biology
“Anti-prostate cancer activity of B-carboline alkaloid enriched extract from Rauwolfia vomitoria” by D.L. Bemis, J.L. Capodice, P. Gorroochurn, A.E. Katz and R. Buttyan – International Journal of Oncology 29: 1065-1073
Check the list of our scientific research publications

Posted in News.